A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

NCT05099848 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Camrelizumab

Sponsor

Shandong Cancer Hospital and Institute

Collaborators

[object Object]